134016Personalised digital therapy and self-management programme for the management of Irritable Bowel SyndromeClosedCollaborative R&DInnovate UKBupa and the NHS estimate that 15-20% of the UK population is affected by Irritable Bowel Syndrome (IBS). IBS is a long-term condition with unexplained symptoms that can severely impact daily life. The objective of this project is to provide an at-hand, personalised, and set of behavioural-change and stress-reduction tools to support self-treatment for IBS sufferers. A treatment mobile app Zemedy has been invented by Bold Health, based on the highly effective gold standard intervention of CBT for IBS, which is included in the NICE guidelines and currently offered offline by therapists. Zemedy will guide users in their treatment such that it can be delivered fully digitally, conveniently at both scale and cost. The main aim of this project is to gain real-world clinical evidence, user-feedback and understanding how Zemedy could be prescribed and accessed within the NHS setting. In parallel, the clinical trial required to gain clinical evidence of the benefits of Zemedy adoption will also be designed and a research protocol developed. In line with the NHS long-term plan, Zemedy will assist with the Digital transformation of the NHS providing digitally enabled and remote care, empowering people to control their therapy options, with a solution that allows patients to undertake treatment at a time and place that is convenient for them. Zemedy will enable patient-centred management of IBS helping treatment compliance and reinforcing the treatment benefits. The project, led by Bold, will utilise its partnerships with leading IBS Charity IBS Network and with Insight national IAPT service to undertake two small user-trials within the NHS setting to generate real-world data, both with patients as well as clinicians. These will provide essential data and qualitative feedback regarding the integration of Zemedy within the current NHS Clinical pathway, and establish usability and acceptability to patients and clinicians. The Health Economic evaluation of Zemedy will also be completed by our sub-contractor CHEATA. The output of the project will provide the stepping-stones required to undertake the necessary clinical-trial of Zemedy to generate evidence that will enabling the adoption of Zemedy across the NHS.